Category: pharmalittle

STAT+: Pharmalittle: We’re reading about Moderna’s $2.25 billion settlement, FDA warning letters, and more Good morning, everyone, and welcome to the middle of the week. Congratulations on making it this far, and remember there are only a few more days until the weekend arrives. So keep plugging away. After all, what are the alternatives? While…

STAT+: Pharmalittle: We’re reading about Trump’s MFN deals, 340B program controversies, and much more Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating because that oh-too-familiar routine of meetings, deadlines, and the like has predictably returned. You knew this would happen, though, so being a little…

STAT+: Pharmalittle: We’re reading about an FDA plan for ultra-rare drugs, Novo cutting GLP-1 drug prices, and more Rise and shine, everyone, another busy day is on the way. And it is getting off to a good start here on the Pharmalot campus, where we have clear blue skies and chilly breezes greeting us today.…

STAT+: Pharmalittle: We’re reading about an FDA official’s speech, a Grail cancer blood test, and much more And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is still shaping up as we…

STAT+: Pharmalittle: We’re reading about TrumpRx questions, drugmakers lowering some prices, and more And so, another working week will soon come to an end. This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is rather modest. Other than enjoying a symphony, we plan to sharpen our shovels and dig…

STAT+: Pharmalittle: We’re reading about FDA voucher worries, weight loss drugs and jet fuel, and more And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is still shaping up as we weigh…

STAT+: Pharmalittle: We’re reading about a potential Merck purchase, a J&J pricing deal with Trump, and more And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is, so far, rather modest. We…

STAT+: Pharmalittle: We’re reading about the U.S. launch of a Wegovy pill, a Chinese biotech incubator, and more Good morning, everyone, and welcome to another working week. We have returned from an extended break, which perhaps many of you enjoyed as well. In any event, we hope that any down time was relaxing and invigorating,…

STAT+: Pharmalittle: We’re reading about obesity drug lawsuits, Ramaswamy’s latest startup, and much more Rise and shine, another busy day is on the way. We can tell because the official mascots got an early start chasing down cats, squirrels, and other creatures darting about the Pharmalot campus. And then there is the noisy parade of…

STAT+: Pharmalittle: We’re reading about Medicare-negotiated drug prices, an FDA voucher program, and more Happy Thanksgiving Eve, Pharmalittle readers. This is Allison, filling in for Mr. Pharmalot. I recently hosted a mini Thanksgiving dinner for friends, and was stumped trying to pick music to play in the background. Why aren’t there any real Thanksgiving songs?…

STAT+: Pharmalittle: We’re reading about a Novo next-gen diabetes drug, a Novartis gene therapy, and more Hello there and happy Tuesday from STAT’s London outpost, with Andrew Joseph here filling in for Mr. Pharmalot for the day. While it feels like things are slowing down stateside ahead of the Thanksgiving holiday, this place is busy…

STAT+: Pharmalittle: We’re reading about a Trump deal with Lilly and Novo, fewer U.S. generic drug plants, and more Good morning, everyone, and welcome to the middle of the week. Congratulations on making it this far, and remember there are only a few more days until the weekend arrives. So keep plugging away. After all,…

STAT+: Pharmalittle: We’re reading about feuds at FDA’s CBER, an antibiotic warning in Europe, and more And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is still coming into focus, but we…

STAT+: Pharmalittle: We’re reading about a bidding war for Metsera, HHS plans for speeding biosimilars, and more Hello, everyone, and how are you today? We are just fine, thank you, despite the steady rain drenching the sleepy Pharmalot campus. Our spirits remain sunny thanks, in part, to sage advice from the Morning Mayor: “Every new…

STAT+: Pharmalittle: We’re reading about a GSK drug’s comeback, a buyer’s club for a Vertex drug, and more And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is still shaping up, but…

STAT+: Pharmalittle: We’re reading about a Moderna setback, CVS playing hardball with Gilead, and more Top of the morning to you, and a fine one it is. Blue skies and comfortable breezes are enveloping the Pharmalot campus, where the official mascots are dozing after chasing varmints. As for us, we are engaged in the usual…

STAT+: Pharmalittle: We’re reading about a troubled Novo plant, pressure on the Novavax board, and much more Top of the morning to you. Gray skies are hovering overhead right now, but our spirits remain sunny, nonetheless. Why? We will trot out a bit of insight from the Morning Mayor, who would say, “Every new day…

STAT+: Pharmalittle: We’re reading about another generic abortion pill, pharma layoffs, and more And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is still shaping up, but we plan to indulge in…

STAT+: Pharmalittle: We’re reading about Trump’s drug-pricing plans, Medicare talks, and more Top of the morning to you. The middle of the week is upon us and, since you made it this far, why not forge ahead? After all, there is always light at the end of the proverbial tunnel. You never know what you…

STAT+: Pharmalittle: We’re reading about a new GSK CEO, AstraZeneca’s stock listing, and more Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so familiar routine of deadlines, online meetings, and phone calls has predictably returned. But what can you do? The world, such…

STAT+: Pharmalittle: We’re reading about Trump’s drug pricing plans, pharma tariffs, and much more And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is still shaping up, but we may rendezvous with…

STAT+: Pharmalitte: We’re reading about a Huntington’s gene therapy success, a low-cost HIV drug, and more Good morning, this is Allison, substituting for Mr. Pharmalot. We may have three months left in the year, but I’m already starting to think about 2026, thanks to a handful of concert announcements and ticket sales opening up over…

STAT+: Pharmalittle: We’re reading about FDA and imported GLP-1 drugs, a race to develop sleep meds, and more Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so familiar routine of deadlines, online meetings, and phone calls has predictably returned. But what can you…

STAT+: Pharmalittle: We’re reading about Trump’s post on Covid data, a Merck cholesterol pill, and more Good morning everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so familiar routine of deadlines, online meetings, and phone calls has predictably returned. But what can you do? The…

STAT+: Pharmalittle: We’re reading about Lilly and a China tech giant, Cassidy and a CDC vaccine panel, and more And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is still shaping up,…

STAT+: Pharmalittle: We’re reading about an AbbVie deal for a psychedelic, Lilly obesity pill trial results, and more Top of the morning to you, and a fine one it is. Clear blue skies and pleasant breezes are wafting across the Pharmalot campus, where the official mascots are foraging for their breakfast and rousing the neighbors.…

STAT+: Pharmalittle: We’re reading about FDA reporting side effects, pharma plants near disaster zones, and more Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so familiar routine of deadlines, online meetings, and phone calls has predictably returned. But what can you do? The…

STAT+: Pharmalittle: We’re reading about conflicts on U.S. vaccine panels, pharma DTC sales, and much more Top of the morning to you, and a fine one it is. Blue skies and unusually cool breezes for this time of year are enveloping the Pharmalot campus, where the official mascots are bounding about the grounds in search…

STAT+: Pharmalittle: We’re reading about a setback for Pfizer, a boost for Novo Nordisk, and much more Good morning everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so familiar routine of deadlines, online meetings, and phone calls has predictably returned. But what can you do?…

STAT+: Pharmalittle: We’re watching Europe moving to reject Elevidys, a FDA panel on SSRI risks, and more Good morning dearest readers, this is Allison, filling in for Mr. Pharmalittle. I’m coming to you with a little bit of coffee envy — yesterday, one of the investors I follow on LinkedIn revealed that he was recently…

STAT+: Pharmalittle: We’re reading about Sarepta conceding to the FDA, the U.S. transplant system, and more Good morning everyone, it’s Jason Mast, filling in for Ed again. Here’s a fun fact about drugs, pulled from Anne Harrington’s “The Mind Fixers,” a fascinating history of psychiatry I’ve recently picked up: After Albert Hoffman synthesized LSD, Sandoz…

STAT+: Pharmalittle: We’re reading about GLP-1 drugs for addiction, FDA funding, and lots more Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so-familiar routine of meetings, deadlines, and messages has returned. But what can you do? There is no pause button to stop…

STAT+: Pharmalittle: We’re reading about a FDA offer on drug reviews, a Moderna Covid approval, and more And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is, so far, rather modest. We…

STAT+: Pharmalittle: We’re reading about Medicare drug negotiations, a Novartis malaria drug, and more Rise and shine, another busy — and steamy — day is on the way. We can tell because the official mascots are spending less time on the dusty Pharmalot grounds and, instead, have curled up by the indoor cool-air blowing machines.…

STAT+: Pharmalittle: We’re reading about Novo’s Wegovy launch gaffes, a former Pfizer exec’s subpoena, and more Top of the morning to you. And a steamy one, it is. In fact, there is more steam rising from the grounds of the Pharmalot campus than from our ritual cup of stimulation; our choice today is marshmallow magic,…

STAT+: Pharmalittle: We’re reading about a FDA AI tool, mRNA as a political reject, and more Top of the morning to you, and a fine one it is. Clear blue skies and pleasant breezes are wafting across the Pharmalot campus, where the official mascots are foraging for their breakfast and rousing the neighbors. This means…

STAT+: Pharmalittle: We’re reading about Trump’s drug-pricing claims, FDA’s Covid vaccine directive, and more And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is still shaping up, but we expect to manicure…

STAT+: Pharmalittle: We’re reading about a Trump drug-pricing plan, an AstraZeneca court loss, and more And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda involves saluting our shortest person — aka the…

STAT+: Pharmalittle: We’re reading about Makary rejecting a reorganization, pharma lobbying against PBMs, and more Hello, everyone, and how are you today? We are doing just fine, thank you, especially since the middle of the week is upon us. After all, we have made it this far so we are determined to hang on for…

STAT+: Pharmalittle: We’re reading about tariffs increasing U.S. drug costs, Trump cuts on drug safety, and more Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so-familiar routine of meetings, deadlines, and messages has returned. But what can you do? There is no pause…

STAT+: Pharmalittle: We’re reading about FDA layoffs hurting user fee programs, pharma tariffs, and more And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is still shaping up. We expect to promenade with…

STAT+: Pharmalittle: We’re reading about Pfizer halting GLP-1 work, FDA use of contractors, and more Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and refreshing because, once again, that predictable routine of meetings, deadlines, and the like has returned. After all, the world keeps spinning. And to…

STAT+: Pharmalittle: We’re reading about a plan to boost U.S. biotech funding, FDA user fees, and more Top of the morning to you, and a fine one it is. Blue skies and comfortable breezes are enveloping the Pharmalot campus, where the official mascots are dozing in their respective corners and assorted wildlife can be seen…